Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Idecabtagene Vicleucel

Placeholder slot
 (I-deh-KAB-tuh-jeen vik-LOO-sel)

This page contains brief information about idecabtagene vicleucel and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Abecma
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Idecabtagene vicleucel is approved to treat:

It is used in adults who have received at least two lines of treatment that included an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Idecabtagene vicleucel is only available as part of a program called Abecma REMS (Risk Evaluation and Mitigation Strategies).

More About Idecabtagene Vicleucel

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Idecabtagene Vicleucel - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Understanding the Risk of Second Cancers After CAR T-Cell Therapy

Targeted Therapy to Treat Cancer

T-cell Transfer Therapy

CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers

Clinical Trials Accepting Patients

Find Clinical Trials for Idecabtagene Vicleucel - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email